Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Dec 5;96(1):67–72. doi: 10.1038/sj.bjc.6603508

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Detection of degranulating cytotoxic T lymphocytes at the site of tumour treatment with PDT, γ-inulin, or their combination. Subcutaneous MCA205 tumours were treated with ce6-PDT and/or γ-inulin as described for Figure 3. At 3 days after therapy, tumours or remnants collected at the treatment site were taken for preparing single-cell suspensions that were stained with antibodies against CD107a, CD8, and CD45 antigens and analysed by flow cytometry. (A) Representative example of staining of a PDT+γ-inulin sample showing FITC fluorescence intensity in a.u. per cell (CD107a and its isotype control) of the gated population staining positively for PerCP-Cy5.5 (CD45) and PE (CD8) and (B) percentage of CD107a-positive cytotoxic T lymphocytes in total cellular populations detected in different treatment groups. N=4; bars are s.d. ^*Statistically significant difference compared to untreated tumours group; ^**statistically significant difference compared to γ-inulin only and PDT only groups.